Biorchestra Co., Ltd.

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
Biorchestra is an innovative biotechnology company with an RNA-based therapy platform that can control both single and multiple mRNAs. In addition, our proprietary “Smart Drug Delivery System” can safely and effectively transport drugs to desired locations, thereby enabling us to develop optimal RNA drugs. We have developed multiple mRNA-regulated microRNA antisense oligonucleotides (ASO) with a brain-specific drug delivery system as therapeutics to control diseases, such as neurodegenerative diseases caused by various protein dysfunctions. Unlike DNA-targeted therapeutics that can be permanently inserted into the chromosome, RNA-based therapeutics are temporary, thus reducing irreversible cellular DNA changes that increase the risk of tumorigenesis.
Our other RNA platform, the mRNA drug platform, is an mRNA system capable of expressing viral antigens or cancer neoantigens.
And BMD-001, a treatment for Alzheimer's disease, is currently being developed in the pre-clinical stage.
Company Type:
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Korea - South Korea
Year Founded:
2016
Main Therapeutic Focus:
Lead Product in Development:
RNA Therapeutics
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CEO / President
Biorchestra Co., Ltd.